The in vitro activity of DX-619, a new des-F(6)-quinolone, was tested against staphylococci and compared to those of other antimicrobials. DX-619 had the lowest MIC ranges/MIC 50 s/MIC 90 s (g/ml) against 131 Staphylococcus aureus strains (<0.002 to 2.0/0.06/0.5) and 128 coagulase-negative staphylococci (0.004 to 0.25/0.016/ 0.125). Among strains tested, 76 S. aureus strains and 51 coagulase-negative staphylococci were resistant to ciprofloxacin. DX-619 had the lowest MIC 50 /MIC 90 values against 127 quinolone-resistant staphylococci (0.125/0.5), followed by sitafloxacin (0.5/4), moxifloxacin (2/8), gatifloxacin (4/16), levofloxacin (16/>32), and ciprofloxacin (>32/>32). Raised quinolone MICs were associated with mutations in GyrA (S84L) and single or double mutations in GrlA (S80F or Y; E84K, G, or V) in all S. aureus strains tested. A recent vancomycinresistant S. aureus (VRSA) strain (Hershey) was resistant to available quinolones and was inhibited by DX-619 at 0.25 g/ml and sitafloxacin at 1.0 g/ml. Vancomycin (except VRSA), linezolid, ranbezolid, tigecycline, and quinupristin-dalfopristin were active against all strains, and teicoplanin was active against S. aureus but less active against coagulase-negative staphylococci. DX-619 produced resistant mutants with MICs of 1 to >32 g/ml after <50 days of selection compared to 16 to >32 g/ml for ciprofloxacin, sitafloxacin, moxifloxacin, and gatifloxacin. DX-619 and sitafloxacin were also more active than other tested drugs against selected mutants and had the lowest mutation frequencies in single-step resistance selection. DX-619 and sitafloxacin were bactericidal against six quinolone-resistant (including the VRSA) and seven quinolone-susceptible strains tested, whereas gatifloxacin, moxifloxacin, levofloxacin, and ciprofloxacin were bactericidal against 11, 10, 7, and 5 strains at 4؋ MIC after 24 h, respectively. DX-619 was also bactericidal against one other VRSA strain, five vancomycin-intermediate S. aureus strains, and four vancomycin-intermediate coagulase-negative staphylococci. Linezolid, ranbezolid, and tigecycline were bacteriostatic and quinupristin-dalfopristin, teicoplanin, and vancomycin were bactericidal against two, eight, and nine strains, and daptomycin and oritavancin were rapidly bactericidal against all strains, including the VRSA. DX-619 has potent in vitro activity against staphylococci, including methicillin-, ciprofloxacin-, and vancomycin-resistant strains.
The emergence of methicillin-and quinolone-resistant, and recently glycopeptide-intermediate, staphylococci, as well as the propensity of these organisms to cause serious systemic infections in immunocompromised hosts, necessitates other therapeutic modalities (2, 9, 10, 19, 24, 29) . During 2002, two clinical strains of vancomycin-resistant Staphylococcus aureus (VRSA) carrying vanA, one from Detroit, Mich., and one from our hospital, have been isolated (3, 28) . Several months ago, a third VRSA was isolated in New York city (14) .
Most methicillin-resistant staphylococci are also resistant to available quinolones, such as ciprofloxacin and levofloxacin (8, 23) . Thus, the latter group of compounds may not be safely used in empirical therapy of patients with methicillin-resistant staphylococcal infections. DX-619 is a new des-F(6)-quinolone ( Fig. 1 ) with excellent activity against gram-positive organisms. The current study examined (i) the activity of DX-619 against 259 methicillin-and quinolone-susceptible and -resistant staphylococci compared to those of sitafloxacin, ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, vancomycin, teicoplanin, linezolid, ranbezolid, tigecycline, and quinupristin-dalfopristin by agar MIC testing and those of daptomycin and oritavancin by microdilution; (ii) the activities of the abovementioned compounds against 13 staphylococci by time-kill analysis; and (iii) the capabilities of DX-619, sitafloxacin, moxifloxacin, gatifloxacin, and ciprofloxacin to select for resistance in 10 staphylococci. 24 -h incubation. The antibacterial susceptibilities of VRSA strains were tested by the macrodilution method using cation-adjusted Mueller-Hinton broth (18) .
Time-kill studies. Tubes containing 5 ml cation-adjusted Mueller-Hinton broth (Difco) with doubling antibiotic concentrations were inoculated with 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml and incubated at 35°C in a shaking water bath. The methods were those described previously by our group (21) , and added calcium was used for daptomycin testing (18) . The strains used for time-kill studies were tested by the double-disk test for macrolide resistance, using erythromycin (30 g) and clindamycin (2 g) disks.
Time-kill assays were analyzed by determining the number of strains that yielded ⌬log 10 CFU/ml of Ϫ1, Ϫ2, and Ϫ3 at 0, 3, 6, 12 , and 24 h compared to counts at time zero. Antimicrobials were considered bactericidal at the lowest concentration that reduced the original inoculum by Ն3 log 10 CFU/ml (99.9%) at each of the time periods and bacteriostatic if the inoculum was reduced by 0 to Ͻ3 log 10 CFU/ml. The problem of bacterial carryover was addressed by dilution as described previously (21) . Six strains were not tested with ciprofloxacin, four with levofloxacin, and one each with gatifloxacin, moxifloxacin, and vancomycin due to resistance to the individual antibiotics.
Multistep resistance selection. Ten staphylococcal strains, including three ciprofloxacin-susceptible (MIC Ͻ 2 g/ml) and seven ciprofloxacin-resistant (MIC Ͼ 32 g/ml) strains, were used in the study. Initial inocula (ca. 5 ϫ 10 8 to 1 ϫ 10 9 CFU/ml) were prepared by suspending growth from an overnight Trypticase soy blood agar plate (Difco) in CAMHB. Glass tubes containing 1 ml of antibiotic-free or antibiotic-supplemented CAMHB were inoculated; antibiotic concentrations in the tubes ranged from four doubling dilutions above to three doubling dilutions below the MIC of each drug for each strain. The tubes were incubated at 35°C for 24 h. Daily passages were then performed for up to 50 days by taking a 10-l inoculum from the tube nearest the MIC (usually 1 to 2 dilutions below) which had the same turbidity as the antibiotic-free controls. From time to time, an aliquot from a tube used as an inoculum for the successive passage was frozen at Ϫ70°C in double-strength skim milk for subsequent analysis. When an MIC for a strain stabilized at Ͼ32 g/ml (minimum amount, 14 passages) during four successive passages, serial transfer in the presence of subinhibitory concentrations of antibiotic was discontinued, and the strains were subjected to 10 passages in antibiotic-free medium to check the stability of acquired mutants. To determine whether resistant isolates obtained during and at the end of serial passages were indeed derived from the parental strains, the parental strains, intermediary clones with elevated MICs, and clones obtained after the final passage were examined by pulsed-field gel electrophoresis using a CHEF DR III apparatus (BioRad, Hercules, CA) as previously described (1, 17) .
Single-step resistance studies. The frequency of spontaneous single-step mutation was determined by spreading cultures (approximately 10 10 CFU/ml) in a 100-l volume of phosphate-buffered saline. Mueller-Hinton agar plates (100-mm diameter) contained each compound at 1ϫ, 2ϫ, 4ϫ, and 8ϫ MIC. The plates were incubated aerobically at 35°C for 24 h. Confluent growth at 1ϫ MIC with initial inoculum dilutions of 10 Ϫ1 , 10 Ϫ2 , 10 Ϫ3 , and Ͼ300 colonies at 10
Ϫ5
made it unfeasible to reliably interpret growth on plates. Additionally, quinolone MICs taken from growth on these plates were, in Ͼ90% of cases, equal to or 1 dilution above those of the parent strains. By contrast, single colonies were reproducibly found at drug concentrations above the MIC. We therefore elected to analyze results obtained at 2ϫ, 4ϫ, and 8ϫ MIC only. Because colonies obtained at these higher MICs often occurred on a background of confluent growth (see above), retesting by agar dilution MIC was performed. To ensure the reproducibility and reliability of results, resistance in single-step studies was defined as a MIC Ͼ4-fold higher than that for the parent. The resistance frequency was calculated at each MIC as the number of resistant colonies per inoculum. MICs of resistant clones. The MIC of each resistant clone to each of the quinolones in resistance selection studies was determined by broth macrodilution, as described above. The effect of reserpine (20 mg/liter dissolved in dimethyl sulfoxide) on MICs was also determined.
Determination of quinolone resistance mechanism. The PCR method was used to amplify quinolone resistance determinant regions (QRDR) in the gyrA, gyrB, grlA, and grlB genes using primers and cycling conditions described previously (7, 15) . Template DNA for PCR was prepared using InstaGen Matrix, as recommended by the manufacturer (Bio-Rad Laboratories, Hercules, CA). After amplification, PCR products were purified from excess primers and nucleotides using a QIAquick PCR Purification kit (QIAGEN, Valencia, CA) and sequenced directly using the CEQ8000 Genetic Analysis System (Beckman Coulter, Fullerton, CA).
Determination of macrolide and methicillin resistance mechanisms. The presence of genes coding for macrolide resistance, ermA, ermB, ermC, and msrA, were studied by PCR as described by Sutcliffe and coworkers (27) . The methicillin resistance determinant mecA gene was amplified by PCR from methicillinresistant strains by using specific primers (20) . Tables 1  and 2 . DX-619 MIC 50 and MIC 90 values were 0.06 and 0.5 g/ml, respectively, against S. aureus and 0.016 and 0.125 g/ ml, respectively, against coagulase-negative staphylococci. aureus were 0.008 and 0.016 g/ml against ciprofloxacin-susceptible strains and 0.125 and 1.0 g/ml against ciprofloxacinresistant strains, and for coagulase-negative strains they were 0.016 and 0.03 g/ml for ciprofloxacin-susceptible and 0.125 and 0.25 g/ml for ciprofloxacin-resistant strains, respectively. DX-619 had the lowest MIC 50 s and MIC 90 s against ciprofloxacin-resistant strains (0.125 and 0.5 g/ml), followed by sitafloxacin (0.5 and 4 g/ml), moxifloxacin (2 and 8 g/ml), gatifloxacin (4 and 16 g/ml), levofloxacin (16 and Ͼ32 g/ml), and ciprofloxacin (Ͼ32 and Ͼ32 g/ml) against all quinoloneresistant staphylococci tested and for S. aureus as well as coagulase-negative staphylococci when they were analyzed separately (Table 2 ). For the three coagulase-negative strains, which were intermediate to ciprofloxacin, the MICs for DX-619 were 0.016 to 0.03 g/ml. MICs of other quinolones were significantly higher in quinolone-resistant strains, with sitafloxacin being next most active against all strains. Linezolid MICs, especially against coagulase-negative strains, were often at least 1 to 2 dilutions higher than that of ranbezolid. Vancomycin MICs were low against all strains, but teicoplanin was much less active against coagulase-negative Corresponding values for daptomycin were 0.125 to 2.0 g/ml and 0.5 g/ml, respectively. The Hershey VRSA strain (VRS2) had the following MICs: DX-619, 0.25 g/ml; sitafloxacin, 1.0 g/ml; ciprofloxacin, Ͼ64.0 g/ml; levofloxacin, 32.0 g/ml; gatifloxacin, 8.0 g/ml; on November 8, 2017 by guest http://aac.asm.org/ moxifloxacin, 4.0 g/ml; vancomycin, 32.0 g/ml; teicoplanin, 4.0 g/ml; linezolid, 1.0 g/ml; ranbezolid, 1.0 g/ml; tigecycline, 0.125 g/ml; daptomycin, 0.5 g/ml; oritavancin, 0.25 g/ml; and quinupristin-dalfopristin, 1.0 g/ml.
RESULTS

Susceptibility. Staphylococcal MICs are listed in
Mechanism of quinolone resistance. Seventy-six S. aureus strains resistant to ciprofloxacin were studied for the presence of mutations in quinolone resistance-determining regions in gyrA, gyrB, grlA, and grlB. The strains tested had at least one mutation in GyrA and one mutation in GrlA (Table 3 ). All quinolone-resistant S. aureus strains had the same mutation in GyrA: serine (S) at position 84 was replaced by leucine (L). Only four strains had a mutation in GyrB: arginine (R) at position 404 was replaced by leucine. All 76 strains had mutations in subunit A and only 18 in subunit B of topoisomerase IV. The modifications in GrlA were at position 80 by changing serine to phenylalanine (F) or tyrosine (Y) or at position 84 by changing glutamic acid (E) to lysine (K). Thirteen strains had double mutations; the mutations at position 80 were associated with a second mutation at position 84, by changing glutamic acid to glycine (G), lysine, or valine (V) ( Table 3) .
The MIC distributions by number of mutations are shown in Fig. 2 . The mode was 0.125 g/ml for DX-619 among strains with one mutation in QRDR of GrlA and 2, 4, 8, and Ͼ32 g/ml for moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin, respectively. Sitafloxacin (data not shown) gave an MIC distribution between those of DX-619 and moxifloxacin. In strains with double mutations in GrlA, the mode was 1 g/ml for DX-619 and 16 g/ml, 16 g/ml, Ͼ32 g/ml, and Ͼ32 g/ml for moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin, respectively. The presence of a mutation at position 84 in addition to the mutation at position 80 increased the MICs for the quinolones tested at least eightfold.
Multistep resistance selection studies. Initial MICs (g/ml) were as follows: DX-619, 0.004 to 0.5; ciprofloxacin, 0.125 to Ͼ64; sitafloxacin, 0.03 to 4; moxifloxacin, 0.06 to 16; and gatifloxacin, 0.06 to 16. All studied quinolones caused Ͼ4-fold increases or MICs of Ͼ32 g/ml in less than 50 days. In three initially ciprofloxacin-susceptible strains, Ͼ4-fold increases in MICs were achieved within 10 to 20 days for DX-619, sitafloxacin, moxifloxacin, and ciprofloxacin and, with the exception of one strain that developed resistance after 43 days, within 20 to 30 days for gatifloxacin. After 50 days of continuous antibiotic exposure, the MICs of these strains increased to 0.25 to 16 g/ml for DX-619, 32 to Ͼ32 g/ml for ciprofloxacin, 16 to Ͼ32 g/ml for sitafloxacin, Ͼ32 g/ml for moxifloxacin, and 16 to Ͼ32 g/ml for gatifloxacin. In all initially ciprofloxacin-resistant strains, moxifloxacin and gatifloxacin MICs increased to Ͼ32 g/ml, sitafloxacin MICs increased to 16 to Ͼ32 g/ml, and DX-619 MICs increased to 1 to Ͼ32 g/ml after 50 days.
Cross-resistance occurred in all clones with acquired quinolone resistance ( Table 4 ). The MICs of DX-619 were lowest against the resistant mutants selected (with the exception of DX-619-resistant mutants originating from SA096 and SA077, whose DX-619 MICs were higher than those of sitafloxacin), followed by those of sitafloxacin, moxifloxacin, gatifloxacin, and ciprofloxacin. For moxifloxacin-, gatifloxacin-, and ciprofloxacin-resistant clones, DX-619 MICs were Ն2 dilutions lower than the corresponding sitafloxacin MICs (except for the moxifloxacin-resistant clone of CN158 and the gatifloxacin-resistant clone of CN111). All selected mutants had stable resistance phenotypes, with no strains showing Ͼ1 dilution step decrease in MICs after 10 consecutive passages in antibiotic-free medium.
Treatment with the efflux inhibitor reserpine lowered ciprofloxacin or sitafloxacin MICs in only 2/10 parent strains (ciprofloxacin MICs in strain CN227, 32 g/ml to 8 g/ml; sitafloxacin MICs in strain SA078, 2 g/ml to 0.5 g/ml with reserpine [data not shown in Table 4 ]). The contributions of the efflux mechanism to MIC levels differed with selective agents among mutants (Table 4) . Of 10 DX-619-selected mutants, 6 had efflux for DX-619 and/or sitafloxacin. Sitafloxacinresistant selected mutants had efflux for DX-619 (6/10) and sitafloxacin (5/10). Five gatifloxacin-resistant selected mutants had efflux for DX-619 and/or sitafloxacin. The ciprofloxacinresistant clone of SA096 had efflux for all studied quinolones, while a ciprofloxacin-resistant clone of SA505 had efflux for sitafloxacin and gatifloxacin (Table 4) .
We studied the QRDR nucleotide sequences of the gyrA, gyrB, grlA, and grlB genes of all mutant strains originating from S. aureus. The mutations identified are summarized in Table 4 . a Among the strains tested, SA8, SA9, SA12, CN3, CN6, and CN20 were susceptible and SA13, SA16, SA19, VRSA, CN5, CN11, and CN18 were resistant to methicillin.
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Four out of six S. aureus parent strains were initially ciprofloxacin resistant; all had an S84L mutation in GyrA and either an S80F or an S80Y mutation in GrlA. Exposure to DX-619, sitafloxacin, moxifloxacin, and gatifloxacin in these strains resulted in various mutations in all four studied genes. In GyrA, three isolates had an E88K/V mutation, one had a G82C mutation, and one had an A119T mutation. In GrlA, the mutations were S81P (one strain) and E84V/A (two strains). Various mutations were found in GyrB: three mutants had a D437E mutation (in combination with V434S in one strain), and five mutants had a P456S mutation either alone (four of five) or with an L457F mutation (one of five). Several different mutations were found in GrlB: D432V (three mutants), S437T (one mutant), R444C (one mutant), E472V (one mutant), and E471K (two mutants).
All mutants (except a ciprofloxacin-resistant mutant of SA096) selected from two originally ciprofloxacin-susceptible strains acquired mutations in GyrA (S84L [except for the moxifloxacin-resistant mutant of strain SA505] and E88K [in the sitafloxacin-resistant mutant of SA505]) and GrlA (S80F/Y and/or E84K). The ciprofloxacin-resistant mutant of SA096 had no mutations in any of the QRDR; however, it had efflux for all studied quinolones. Additionally, three quinolone-resistant mutants of SA505 had L433I plus P456S mutations in GyrB (selected with moxifloxacin), a P451S mutation in GrlB (selected with sitafloxacin), and an S433T mutation in GrlB (selected with gatifloxacin). The DX-619-resistant mutant of SA096 had an E472G mutation in GrlB.
Single-step resistance selection studies. Frequencies of single-step mutations with DX-619, sitafloxacin, moxifloxacin, and gatifloxacin at 2ϫ, 4ϫ, and 8ϫ MIC are summarized in Table  5 . As can be seen, DX-619 and sitafloxacin had the lowest mutation frequencies of all quinolones at all MICs tested, with DX-619 selecting for fewer mutants than sitafloxacin.
Time-kill study. The staphylococcal MICs for the 13 strains tested by time-kill are presented in Table 6 , and the results of time-kills are summarized in Table 7 and depicted graphically in Fig. 3 . Among six S. aureus strains used for time-kill studies, three were resistant to erythromycin, two had an ermA gene, and one carried both ermA and ermB. The Hershey VRSA strain (VRS2) also had both ermA and ermB genes. Three of six S. aureus strains were resistant to ciprofloxacin. Three of six coagulase-negative staphylococci were resistant to erythromycin: two had an ermA and one had an ermC gene. Two of six strains were resistant to ciprofloxacin.
DX-619 and sitafloxacin were bactericidal at 4ϫ MIC after 24 h against all strains tested, regardless of their resistance to other quinolones. All other quinolones gave similar rates of killing relative to higher MICs. The killing activities of ciprofloxacin against five ciprofloxacin-resistant staphylococci and the VRSA strain were not studied.
Linezolid, ranbezolid, tigecycline, and quinupristin-dalfopristin were mainly bacteriostatic after 24 h. Vancomycin, at 4ϫ MIC, was bactericidal against nine strains after 24 h. Oritavancin and daptomycin had bactericidal effects for all strains after 12 h at 4ϫ MIC. Daptomycin and oritavancin were both rapidly bactericidal, with activity demonstrable as early as 3 h. DX-619 and sitafloxacin were bactericidal at 2ϫ MIC against the VRSA strain after 3 to 6 h.
The killing activities of DX-619 were also tested against the In the present study, we found that DX-619 produced resistant clones with MICs of 1 to Ͼ32 g/ml after Ͻ50 days of antibiotic selection compared to 16 to Ͼ32 g/ml with ciprofloxacin-, sitafloxacin-, moxifloxacin-, and gatifloxacin-resistant clones. Cross-resistance studies showed that DX-619 and sitafloxacin had lower MICs than ciprofloxacin, moxifloxacin, and gatifloxacin in the clones resistant to the latter group of quinolones. In addition, DX-619 and sitafloxacin also had the lowest mutation frequencies of all quinolones at all MICs tested in single-step tests. We have no explanation for the confluent growth (which on retesting did not represent resistant mutants) found at 1ϫ MIC in single-step experiments.
All but one resistant clone obtained during multistep selection had mutations in GyrA (S84L and E88K) and GrlA (S80F/Y and E84K/V/A). Some of the strains had mutations in GyrB and GrlB; however, no correlation was observed between the presence of mutations in the last two, in addition to mutations in GyrA and GrlA, and an increase in quinolone MICs. Also, though testing with reserpine demonstrated the presence of an efflux pump in some resistant clones, it did not seem to contribute to quinolone resistance (MICs for the relevant drugs were not substantially higher than those in clones without efflux present). The only exception was the ciprofloxacin-resistant clone of SA096, which did not have any detectable mutations present in the QRDR but had efflux for all tested quinolones. The clinical significance of a strain with the latter genotype is unknown.
The MIC and time-kill results for other compounds tested against staphylococci are similar to those described previously (4-6, 8, 9, 11, 16, 24, 26) : daptomycin and oritavancin had the most rapid bactericidal activities, followed by vancomycin, teicoplanin, and quinupristin-dalfopristin, with tigecycline, linezolid, and ranbezolid being mainly bacteriostatic. The bacteriostatic activity of quinupristin-dalfopristin resulted from the presence of erm genes in seven strains; in the remaining six strains, the lack of the drug's usual rapid bactericidal activity could not be explained.
The results of this study indicate a potential role for DX-619 in the treatment of staphylococcal infections. However, interpretation of these in vitro results must be complemented by toxicity and pharmacokinetic-pharmacodynamic studies before the drug can be recommended for clinical testing.
